Out-licensing

Glycan Microarray Devices for Quantitative Detection Analysis of Cancer

Introduction/Background

Carbohydrate associated cancer antigens is a family of carbohydrates that are highly expressed on a variety of cancers. Understanding their roles in cancer progression will lead to the development of new therapeutics and high-sensitivity diagnostics for caner. Globo H is a member of this family, which is highly expressed on breast cancer cells.

Aims/Hypothesis

Novel methods are required for the detection analysis of cancer.

Results

The invention relates to the development of the glycan microarray of Globo H and its analogues for measurement of the dissociation constants on surface (KD, surf) with three different monoclonal antibodies (VK-9, Mbr1 and anti-SSEA-3), in order to deduce their binding specificity.

The glycan microarray is useful for detecting the amount of antibodies present in the plasma of breast cancer patients and normal blood donors. It was shown that the amount of antibodies against Globo H from breast cancer patients were significantly higher than normal blood donors and increased as the disease progressed, providing a new tool for possible breast cancer diagnosis.

Conclusion

We have developed a new platform for use to monitor the immune response to carbohydrate epitopes after vaccine therapy or during the natural course of cancer.

Relevance/Opportunity

Please enquire quoting reference no. 28A-970408 regarding licensing or codevelopment partnerships.

Preclinical